Enlivex (ENLV) Non Operating Interest Expenses (2013 - 2020)
Enlivex (ENLV) posted Non Operating Interest Expenses of $2.1 million for Q4 2020, up 1051.57% on a QoQ basis from -$223000.0 in Q3 2020, and up 27.29% year-over-year from $1.7 million in Q1 2020.
Analysis
Enlivex (ENLV) Non Operating Interest Expenses (2013 - 2020) Analysis & Trends
Enlivex has reported Non Operating Interest Expenses for 7 years, with the latest figure at $2.1 million in Q4 2020.
- On a quarterly basis, Non Operating Interest Expenses rose 27.29% year-over-year to $2.1 million in Q4 2020; TTM through Dec 2020 was $2.8 million, a 139.01% increase from a year earlier, with the FY2025 full-year figure at $29000.0, down 91.76% from the prior year.
- Non Operating Interest Expenses was $2.1 million for Q4 2020 at Enlivex, up from -$223000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $2.1 million in Q4 2020, with the low at -$358000.0 in Q1 2019.
- Average Non Operating Interest Expenses over 4 years is $351615.4, with a median of $5000.0 recorded in 2018.
- The largest YoY upside for Non Operating Interest Expenses was 33240.0% in 2019 against a maximum downside of 34100.0% in 2019.
- Over 4 years, Non Operating Interest Expenses stood at $592000.0 in 2017, then sank by 99.16% to $5000.0 in 2018, then surged by 33240.0% to $1.7 million in 2019, then advanced by 27.29% to $2.1 million in 2020.
- The last three Non Operating Interest Expenses figures came in at $2.1 million (Q4 2020), -$223000.0 (Q3 2020), and $897000.0 (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Enlivex | 3.17 Mn | -2.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 2.12 Mn |
| Sep 30, 2020 | -223,000.00 |
| Jun 30, 2020 | 897,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Dec 31, 2019 | 1.67 Mn |
| Sep 30, 2019 | -342,000.00 |
| Jun 30, 2019 | 202,000.00 |
| Mar 31, 2019 | -358,000.00 |
| Dec 31, 2018 | 5,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Jun 30, 2018 | -3,000.00 |
| Mar 31, 2018 | 15,000.00 |
| Dec 31, 2017 | 592,000.00 |
| Jun 30, 2015 | -55,000.00 |
| Mar 31, 2015 | -21,000.00 |
| Dec 31, 2014 | 50,000.00 |
| Sep 30, 2014 | -19,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 4,000.00 |
| Dec 31, 2013 | -7,000.00 |